DaVita HealthCare Partners Inc. announced Monday that Garry E. Menzel will join the company in mid-September and eventually take over the role of chief financial officer.
Menzel will start as senior vice president of finance and transition into the CFO role after the Denver-based company files its report for the quarter that ends Sept. 30.
Menzel, 48, most recently held the positions of chief operating officer and CFO at Regulus Therapeutics Inc., a publicly-traded biopharmaceutical company.
Prior to joining Regulus in 2008, he had a 14-year career on Wall Street where he was a Managing Director and Global Head of Life Sciences for Credit Suisse and a Managing Director and Global Head of Biotechnology for Goldman Sachs. Menzel also spent several years as a strategy consultant for Bain & Company.
Jim Hilger, who has served as interim CFO since 2012, will continue in his role as the company’s chief accounting officer, a position he has held since 2010.
“We believe we have found an executive with a versatile set of skills, from advanced finance to demonstrated strategic capabilities,” said Kent Thiry, DaVita CEO said in a statement. “Given the nimbleness that is required for all healthcare providers we are excited to have Garry join our leadership team.”
Andy Vuong : 303-954-1209, avuong@denverpost.com or
